A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma

Sponsor:

SWOG

Sponsor Study ID:

SN2426

CTO #:

104387

NCT Number:

NCT07042295

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Other Skin

Study Objectives:

Safety run-in (Cohort A): To evaluate the safety and preliminary efficacy of amivantamab monotherapy in patients with locoregionally incurable or metastatic cutaneous squamous cell carcinoma and an active immunosuppressed condition. Randomized comparison (Cohort B): To compare progression-free survival (PFS) of amivantamab monotherapy versus cetuximab monotherapy in patients with locoregionally incurable or metastatic cutaneous squamous cell carcinoma and an active immunosuppressed condition.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)